Glucose-6-phosphate dehydrogenase (G6PDH) catalyzes the oxidation of glucose-6-phoshate to 6-phospho-gluconolactone with the concomitant reduction of NADP + to NADPH. In solution, the recombinant human G6PDH is known to be active as dimers and tetramers. To distinguish between the kinetic properties of dimers and tetramers of the G6PDH is not trivial. Steady-state kinetic experiments are often performed at low enzyme concentrations, which favor the dimeric state. The present work describes two novel human G6PDH mutants, one that creates four disulfide bonds among apposing dimers, resulting in a 'cross-linked' tetramer, and another that prevents the dimer to dimer association. The functional and structural characterizations of such mutants indicate the tetramer as the most active form of human G6PDH.
The enzyme Glucose-6-phosphate dehydrogenase, E.C. 1.1.1.49 (G6PDH) catalyzes the first step of the pentose phosphate pathway (PPP), which consists of the oxidation of glucose-6-phoshate (G6P) to 6-phosphogluconolactone with the concomitant reduction of NADP + to NADPH. G6PDH plays a central role in cellular homeostasis by supplying NADPH for several biosynthetic processes and for the maintenance of redox balance. G6PDH deficiency is the most common human enzymatic defect disorder; it causes hemolytic anemia triggered by the exposure of red blood cells to oxidant agents [1] . Despite this negative effect, G6PDH deficiency confers some level of resistance against malaria, being found in higher frequency in regions where malaria is endemic [2] . Although G6PDH is considered a 'housekeeping' enzyme, its expression level, intracellular translocation, and posttranslation (phosphorylation) modification have been demonstrated to be regulated, both positively and negatively, by different signaling factors (revised by Stanton, 2010 [3] ). Altered G6PDH regulation can affect cellular metabolism and propagation, with direct implication to cancer [4] , metabolic syndrome, and vascular disease progression [5] .
The active forms of the human G6PDH are associated with dimeric and tetrameric states, but not to monomers. Equilibria exist between tetramers to dimers and dimers to monomers, but not between tetramers directly to monomers. Moreover, NADPH shifts the equilibrium from active dimers to inactive monomers [6] . The equilibrium between dimer and tetramer is affected by ionic strength, pH, and enzyme concentration; pH below 7.2, low ionic strength, high protein concentration favor the tetrameric state [7] .
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Additionally, the binding of a structural NADP + to a site different from the catalytic one, also favors the tetrameric conformation [8] . Crystallographic structures of recombinant human G6PDHs present the protein at the tetrametric state, even when crystals were grown at pH 5.8 [9] .
Usually standard G6PDH steady-state kinetic experiments are performed at a low enzyme concentration by measuring the fluorescence or absorbance relative to NADPH production. Once the G6PDH dimer is predominant at low protein concentration, one can assume that data retrieved from such kinetic experiments are related to the dimeric form of the enzyme. In order to compare kinetic parameters between dimers and tetramers it would be necessary to establish a 'cross-linked' G6PDH tetramer that would resist dissociation once diluted during the kinetic experiments.
In the present work, we describe the design of two new G6PDH mutants, one that prevents the tetramer formation and another that stabilizes the tetramer by the introduction of four disulfide bridges between adjacent dimers. The kinetic characterization of those mutants indicates relevant differences between dimers and tetrames of human G6PDH.
Materials and methods

Site-directed mutagenesis and preparation of recombinant G6PDHs
The cloning of the expression vector pET_SU-MO_HsDG6PDH encoding for a short construction of HsG6PDH (HsDG6PDH, residues 29-511) with a N-terminal His-SUMO tag was described elsewhere [10] . The single HsDG6PDH mutants A277C and E347A (HsDG6PDH_ A277C and HsDG6PDH_E347A, respectively) were generated using the QuickChange II XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA), following the manufacturer's instructions and with the oligonucleotides: The expression and purification of both HsDG6PDH mutants followed the protocol previously established for HsDG6PDH [10] . Briefly, Escherichia coli BL21 (DE3) cells harboring either HsDG6PDH_A277C or HsDG6PDH _E347A vectors were grown in ZYM5052 autoinduction medium [11] for 48 h at room temperature and 250 rpm.
Cells were harvested, lysed by sonication, clarified by centrifugation, and submitted to metal affinity chromatography (Ni-NTA, Invitrogen, Carlsbad, CA, USA). The His-SUMO tag was cleaved by the addition of ULP-1 protease nickel charge resin and HsDG6PDH mutants were recovered at resin wash step. Both HsDG6PDH mutants were then concentrated and submitted to a final size exclusion chromatography step.
Size exclusion chromatography
The preparative and analytical size exclusion chromatography were performed using the columns Superdex 200 16/60 (GE Healthcare, Uppsala, Sweden) and Superdex 200 10/30 (GE Healthcare), respectively, in an AKTA purifier FPLC system (GE Healthcare). The proteins were applied at 4 mgÁmL À1 (71 lM) on preparative column. The fractions of the main peak were collected, concentrated, and subjected to analytical chromatography. For HsDG6PDH, two different dilutions were applied: 4 mgÁmL 
Protein crystallization and structure determination
The first crystals of HsDG6PDH_A277C were obtained at 291°C by the hanging-drop vapor diffusion method, following the crystallization conditions published elsewhere [12] . The crystal used to solve the structure was grown from drops made of well buffer containing 100 mM TrisHCl pH 9.0, 200 mM MgCl 2 , 13% PEG 4000 and 20% glycerol and a protein solution comprised of 20 mgÁmL
À1
HsDG6PDH_A277C, 2 mM NADP + , 10 mM G6P, 50 mM Tris-HCl pH 8.0, and 150 mM NaCl. The crystal was flashfrozen and collected at 100 K, at X06DA beamline from the Swiss Lightsource (Villigen, Switzerland), using a PILATUS 2M-F detector (DECTRIS, Baden-Daettwil, Switzerland). Diffraction data were indexed and integrated using XDS [13] , and scaled by SCALA [14] . The structure was solved by molecular replacement, using the HsDG6PDH structure (PDB: 2BH9) as search model, using MOLREP [15] . Restrained refinement was performed using REFMAC [16] and manual rebuilding in Coot [17] . The diffraction data and refinement statistics are shown at table 1. X: logarithm of inhibitor concentration.
Enzyme kinetics
Thermal stability
The thermal stability of HsDG6PDHs was assessed by differential scanning fluorimetry using SYPRO Orange (Sigma-Aldrich) as the fluorescent dye [18] . 25 lL of 5 lM of protein with 59 of SYPRO Orange (in 50 mM Tris-HCl pH 8.0 and 150 mM NaCl) was dispensed in a 96-well microplate. The data were taken on a 7500 PCR Real-Time System (Applied Biosystems), measuring the SYPRO Orange fluorescence (filters recommended by manufacturer) in a temperature range of 20-96°C, in steps of 1°C per minute. The melting temperature (T M ) was retrieved by fitting the normalized fluorescence (% Fluorescence) to sigmoidal curve (Eqn 2), using GRAPHPAD PRISM 5. For data normalization, it was considered as 0% the lowest fluorescence intensity value before the denaturation, and 100%, the highest value after denaturation. All assays were performed in triplicate.
% Fluorescence ¼ 100
X: logarithm of temperature; n: Hill slope.
Results and Discussion
HsG6PDH mutants design
According to Au et al. [19] , the tetramer interface of the wild-type HsG6PDH buries only 706 A 2 per monomer and involves 15 residues, out of which 11 are charged residues. The tetramer is formed by the interaction of dimer AB to CD, and four salt bridges (K275(chain-A)/E347(chain-D), K275(chain-B)/E347 (chain-C), E287(chain-A)/K290(chain-D), and E287 (chain-B)/K290(chain-C)) contribute to stabilize the tetrameric state (Fig. 1) . The electrostatic nature of the tetramer interface demonstrates its sensitivity to pH, ionic strength, and protein concentration. In order to The data in parentheses are for the reflections in the outer resolution shell 2.78-2.65 A.
disrupt the tetramer, residue glutamic acid 347 was mutated to an alanine (E347A). Inspection of residues in the tetramer interface leads us to hypothesize that mutation of alanine 277 to a cysteine would bring its sulfur atom in a favorable orientation to form a disulfide bond with cysteine 294.
Oligomeric state of HsDG6PD mutants
Preparative size exclusion chromatography of HsDG6PD at 4 mgÁmL À1 returns two peaks with elution volumes equivalent to tetrameric and dimeric states ( Fig. 2A) . When samples collected from the peak corresponding to the tetrametic state are pooled together, reconcentrated to 4 mgÁmL
À1
, and loaded into an analytical column, we observed an asymmetrical peak with elution volume corresponding to a trimeric state (Fig. 2B solid line) . This effect may be related to the rapid tetramer-dimer equilibrium, generating an intermediate apparent MW. The same effect was already observed for HsG6PDH at 1 mgÁmL À1 by Wang et al. [8] . However, if the same sample is loaded at lower concentration (0.4 mgÁmL À1 ), a single peak appears with an elution volume characteristic of the dimeric state (Fig. 2B, dashed line) . When the same procedure is applied to the HsDG6PD_E347A mutant, no signal of tetramer is observed in the preparative column, but only the dimer peak (Fig. 2C) . Moreover, when samples collected from the dimeric peak are concentrated to 4 mgÁmL À1 and loaded in the analytical column, the mutant remains as in the dimeric state (Fig. 2D) . For the mutant HsDG6PD_A277C, an increase in the tetramer fraction at the preparative size exclusion chromatography is observed when compared to HsDG6PD (Fig. 2E ) and the mutant remains as a tetramer even after a 10-fold dilution (Fig. 2F) . A minor dimeric fraction of HsDG6PD_A277C is always observed in the preparative run, most probably due to troubles in disulfide bridge formation in bacterial cellular environment.
Structure of HsDG6PD_A277C
Crystals for the mutant HsDG6PD_A277C were obtained in the same crystallization condition described for HsDG6PD [12] . The protein is crystallized in space group F222, with one monomer in the asymmetric unit. The tetramer is formed by the crystallographic 222 symmetry. One G6P is bound to the active site, at the same orientation of previous characterized complex. The present structure revealed a right-handed disulfide bond between cysteine 277 and 294, as clearly seen in the electron density (Fig. 3) . The monomer structure is highly conserved with the published HsDG6PD:G6P structure (PDB: 2BHL), with an average RMSD of 0.39 A and 0.71 A for the main chain and side chain, respectively.
Catalytic properties of HsDG6PD mutant
The measurement of steady-state kinetic parameters requires the enzyme to be in a concentration much Fig. 1 . Tetramer organization of HsG6PDH. The tetramer is formed by the dimers AB and CD. In the boxes the salt bridges which stabilize the tetramer are shown. Also, the proximity between alanine 277 and cysteine 294 in the tetramer interface is highlighted. (The figure was prepared using the structure of PDB entry 2BH9).
lower than its substrates, usually in the nanomolar range. Under such a condition, human G6PDH will be predominantly in dimeric state, but a minority of tetramers might remain. In order to access the catalytic proprieties of distinct oligomeric states from HsDG6PD, we established two new mutants that can be considered to exist exclusively as dimers or tetramers at low protein concentration conditions. Comparison of kinetic parameters among mutants and wild-type G6PDH shows a slight raise in K m values for the HsDG6PD_A277C (Table 2) . While a pronounced increase is observed for k cat parameter. These alterations lead to a gain in catalytic efficiency of HsDG6PD_A277C, as observed by the comparison of its turnover rates to that of HsDG6PD_E347A and wild-type.
An important feature of the human G6PDH is its uncompetitive inhibition by steroids like DHEA. Although that was first described in 1960 [20] , the precise location of the steroid-binding site remains unknown. DHEA inhibition was assessed for the mutants and no significant difference in IC50 values Fig. 2 . Size exclusion chromatography of HsDG6PDH mutants. A, C, and E: Preparative size exclusion of HsDG6PDH, HsDG6PDH_E347A, and HsDG6PDH_A277C, respectively. In gray, the fractions recovered and submitted to analytical size exclusion. B, D, and F: Analytical size exclusion of HsDG6PDH, HsDG6PDH_E347A, and HsDG6PDH_A277C, respectively. The apparent MW calculated for HsDG6PDH_E347A, HsDG6PDH_A277C, and HsDG6PDH at 4 mgÁmL À1 (71 lM) and 0.4 mgÁmL À1 (7.1 lM) were 109, 231, 157, and 100 kDa, respectively. The used calibration curve is at Fig. S1 . The theoretical MW of HsDG6PDH monomer is 56.1 kDa. Dotted lines: HsDG6PDH_A277C tetramer peak (11.58 mL) and HsDG6PDH_E347A dimer peak (13.29 mL).
were observed (Table 2 ). This suggests that the steroid inhibition site was not affected by A277C neither E347A mutations and it must exist independently of the ability of G6PDH to form tetramers.
Stability
The differential scanning fluorimetry assay shows a considerable gain in thermal stability for the HsDG6PD_A277C in comparison to HsDG6PD_E347A and the wild-type (Table 3 ). The melting temperature of the HsDG6PD_A277C is higher than 10 degrees when compared to the other proteins here evaluated. This is an additional feature of this G6PDH mutant that may be explored toward the development of improved enzymatic reagents.
Conclusion
The functional and physiological significance of the interconversion of dimer-tetramer of active HsG6PDH is elusive. The measurement of the tetramer enzymatic activity by steady-state kinetics is hampered by the fact that the protein dilution in the assay favors the dimeric state. Here, we present HsG6PDH mutants that display just one oligomeric state, enabling the study of each form independently. The point mutation E347A prevents the tetramer formation even at high protein concentration, while A277C mutation results in the formation of an interchain disulfide bridge with cysteine 294. This last single mutation leads to the establishment of four disulfide bonds in the tetramer interface, making it stable at low protein concentration. The comparison of the kinetic proprieties of the new mutants indicates that the tetramer is at least fourfold more efficient than the dimer. Moreover, the incorporated disulfide bonds make the tetrameric mutant less susceptible to thermal denaturation. Lastly, the designed mutants are valuable tools for further studies to elucidate the role of the oligomeric state in the function of HsG6PDH.
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